{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:14:55Z","timestamp":1787026495443,"version":"build-2736575974"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Graft versus host disease (GVHD) is the major non-relapse complication associated with allogeneic hematopoietic stem cell transplantation (HSCT). Unfortunately, GVHD occurs in roughly half of patients following this therapy and can induce severe life-threatening side effects and premature mortality. The pathophysiology of GVHD is driven by alloreactive donor T cells that induce a proinflammatory environment to cause pathological damage in the skin, gastrointestinal (GI) tract, lung, and liver during the acute phase of this disease. Recent work has demonstrated that the GI tract is a pivotal target organ and a primary driver of morbidity and mortality in patients. Prevention of this complication has therefore emerged as an important goal of prophylaxis strategies given the primacy of this tissue site in GVHD pathophysiology. In this review, we summarize foundational pre-clinical studies that have been conducted in animal models to prevent GI tract GVHD and examine the efficacy of these approaches upon subsequent translation into the clinic. Specifically, we focus on therapies designed to block inflammatory cytokine pathways, inhibit cellular trafficking of alloreactive donor T cells to the GI tract, and reconstitute impaired regulatory networks for the prevention of GVHD in the GI tract.<\/jats:p>","DOI":"10.3389\/fimmu.2021.779076","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T03:38:22Z","timestamp":1638329902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Aditya","family":"Rayasam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Drobyski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2000","article-title":"Graft-Versus-Host Disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3212","article-title":"Advances in Graft-Versus-Host Disease Biology and Therapy","volume":"12","author":"Blazar","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/bjh.14295","article-title":"Pathogenesis of Acute Graft-Versus-Host Disease: From Intestinal Microbiota Alterations to Donor T Cell Activation","volume":"175","author":"Zeiser","year":"2016","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.05.011","article-title":"History of Graft-Versus-Host Disease","volume":"44","author":"Vriesendorp","year":"2016","journal-title":"Exp Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-514752","article-title":"Current Issues in Chronic Graft-Versus-Host Disease","volume":"124","author":"Soci\u00e9","year":"2014","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-Versus-Host Disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.8.3204","article-title":"Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines","volume":"90","author":"Hill","year":"1997","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2645","article-title":"The Role of Cell-Mediated Cytotoxicity in Acute GVHD After MHC-Matched Allogeneic Bone Marrow Transplantation in Mice","volume":"183","author":"Baker","year":"1996","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2141.2012.09129.x","article-title":"Diagnosis and Management of Acute Graft-Versus-Host Disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and Second-Line Systemic Treatment of Acute Graft-Versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0804-2","article-title":"Treatment and Unmet Needs in Steroid-Refractory Acute Graft-Versus-Host Disease","volume":"34","author":"Malard","year":"2020","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.225","article-title":"Patterns of Infection and Infection-Related Mortality in Patients With Steroid-Refractory Acute Graft Versus Host Disease","volume":"52","author":"Garc\u00eda-Cadenas","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.006668","article-title":"Mouse Models of Graft-Versus-Host Disease: Advances and Limitations","volume":"4","author":"Schroeder","year":"2011","journal-title":"Dis Model Mech"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-862-5:445","article-title":"Influence of Radiation Protocols on Graft-vs-Host Disease Incidence After Bone-Marrow Transplantation in Experimental Models","volume":"109","author":"Schwarte","year":"2005","journal-title":"Methods Mol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/09553000701534572","article-title":"Radiation Protocols Determine Acute Graft-Versus-Host Disease Incidence After Allogeneic Bone Marrow Transplantation in Murine Models","volume":"83","author":"Schwarte","year":"2007","journal-title":"Int J Radiat Biol"},{"key":"B16","article-title":"Lethal Graft-Versus-Host Disease in Mice Directed to Multiple Minor Histocompatibility Antigens: Features of CD8+ and CD4+ T Cell Responses","volume":"9","author":"Korngold","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1006\/geno.2002.6752","article-title":"Genomic Organization of the Interleukin-1 Locus","volume":"79","author":"Taylor","year":"2002","journal-title":"Genomics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1006\/geno.2002.6751","article-title":"A Sequence-Based Map of the Nine Genes of the Human Interleukin-1 Cluster","volume":"79","author":"Nicklin","year":"2002","journal-title":"Genomics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nri2691","article-title":"The IL-1 Family: Regulators of Immunity","volume":"10","author":"Sims","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for Rheumatoid Arthritis: A Systematic Review","volume":"36","author":"Mertens","year":"2009","journal-title":"J Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.8.1915.1915","article-title":"Inhibition of Interleukin-1 by an Interleukin-1 Receptor Antagonist Prevents Graft-Versus-Host Disease","volume":"78","author":"McCarthy","year":"1991","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199312000-00045","article-title":"Interleukin-1 is a Critical Effector Molecule During Cytokine Dysregulation in Graft Versus Host Disease to Minor Histocompatibility Antigens","volume":"56","author":"Abhyankar","year":"1993","journal-title":"Transplantation"},{"key":"B23","article-title":"Interleukin-1 or Tumor Necrosis Factor-Alpha Antagonists do Not Inhibit Graft-Versus-Host Disease Induced Across the Major Histocompatibility Barrier in Mice","volume":"60","author":"Vallera","year":"1995","journal-title":"Transplantation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"631384","DOI":"10.1155\/2015\/631384","article-title":"IL-1 Receptor Blockade Alleviates Graft-Versus-Host Disease Through Downregulation of an Interleukin-1\u03b2-Dependent Glycolytic Pathway in Th17 Cells","volume":"2015","author":"Park","year":"2015","journal-title":"Mediators Inflammation"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130084","article-title":"The Nlrp3 Inflammasome Regulates Acute Graft-Versus-Host Disease","volume":"210","author":"Jankovic","year":"2013","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.4.1342.1342","article-title":"Recombinant Human Interleukin-1 Receptor Antagonist in the Treatment of Steroid-Resistant Graft-Versus-Host Disease","volume":"84","author":"Antin","year":"1994","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199609150-00015","article-title":"A Clinical Phase I\/II Study of Recombinant Human Interleukin-1 Receptor in Glucocorticoid-Resistant Graft-Versus-Host Disease","volume":"62","author":"McCarthy","year":"1996","journal-title":"Transplantation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0985","article-title":"Interleukin-1 Blockade Does Not Prevent Acute Graft-Versus-Host Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Trial of Interleukin-1 Receptor Antagonist in Allogeneic Bone Marrow Transplantation","volume":"100","author":"Antin","year":"2002","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/path.2287","article-title":"TNF-Mediated Inflammatory Disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.166.5.1280","article-title":"Tumor Necrosis Factor\/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease","volume":"166","author":"Piguet","year":"1987","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2109","article-title":"Donor T Cell-Derived TNF is Required for Graft-Versus-Host Disease and Graft-Versus-Tumor Activity After Bone Marrow Transplantation","volume":"101","author":"Schmaltz","year":"2003","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-569046","article-title":"MiR-146a Regulates the TRAF6\/TNF-Axis in Donor T Cells During GVHD","volume":"124","author":"Stickel","year":"2014","journal-title":"Blood"},{"key":"B33","article-title":"Conditioning-Related Toxicity and Acute Graft-Versus-Host Disease in Patients Given Methotrexate\/Cyclosporine Prophylaxis","volume":"7","author":"Deeg","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703258","article-title":"The Kinetics of Circulating Cytokines Including IL-6, TNF-Alpha, IL-8 and IL-10 Following Allogeneic Hematopoietic Stem Cell Transplantation","volume":"28","author":"Min","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.4.1011.1011","article-title":"Increased Serum Levels of Tumor Necrosis Factor Alpha Precede Major Complications of Bone Marrow Transplantation","volume":"75","author":"Holler","year":"1990","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0267","article-title":"Infliximab Use in Patients With Severe Graft-Versus-Host Disease and Other Emerging Risk Factors of Non-Candida Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Cohort Study","volume":"102","author":"Marty","year":"2003","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.04.006","article-title":"Addition of Infliximab to Standard Acute Graft-Versus-Host Disease Prophylaxis Following Allogeneic Peripheral Blood Cell Transplantation","volume":"14","author":"Hamadani","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.03.013","article-title":"TNF-Inhibition With Etanercept for Graft-Versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate With Better Outcomes","volume":"18","author":"Choi","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(08)60532-5","article-title":"Interleukin-6 in Biology and Medicine","volume":"54","author":"Akira","year":"1993","journal-title":"Adv Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/TP.0000000000001452","article-title":"Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade","volume":"101","author":"Jordan","year":"2017","journal-title":"Transplantation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bcp.2015.06.009","article-title":"Biological Effects of Interleukin-6: Clinical Applications in Autoimmune Diseases and Cancers","volume":"97","author":"Ho","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2009-01-197178","article-title":"Blockade of Interleukin-6 Signaling Augments Regulatory T-Cell Reconstitution and Attenuates the Severity of Graft-Versus-Host Disease","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-10-1198","article-title":"Interleukin-6 Modulates Graft-Versus-Host Responses After Experimental Allogeneic Bone Marrow Transplantation","volume":"17","author":"Tawara","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000396","article-title":"IL-6 Dysregulation Originates in Dendritic Cells and Mediates Graft-Versus-Host Disease via Classical Signaling","volume":"134","author":"Wilkinson","year":"2019","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting Interleukin-6 in Inflammatory Autoimmune Diseases and Cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71017-4","article-title":"Addition of Interleukin-6 Inhibition With Tocilizumab to Standard Graft-Versus-Host Disease Prophylaxis After Allogeneic Stem-Cell Transplantation: A Phase 1\/2 Trial","volume":"15","author":"Kennedy","year":"2014","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183434","article-title":"Tocilizumab, Tacrolimus and Methotrexate for the Prevention of Acute Graft-","volume":"103","author":"Drobyski","year":"2018","journal-title":"Haematologica"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009050","article-title":"A Phase 3 Double-Blind Study of the Addition of Tocilizumab vs Placebo to Cyclosporin\/Methotrexate GVHD Prophylaxis","volume":"137","author":"Kennedy","year":"2021","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0065-2776(08)60387-9","article-title":"Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity","volume":"70","author":"Trinchieri","year":"1998","journal-title":"Adv Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-255422","article-title":"Blockade of Interleukin-23 Signaling Results in Targeted Protection of the Colon and Allows for Separation of Graft-Versus-Host and Graft-Versus-Leukemia Responses","volume":"115","author":"Das","year":"2010","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175448","article-title":"Interleukin-23 Secretion by Donor Antigen-Presenting Cells is Critical for Organ-Specific Pathology in Graft-Versus-Host Disease","volume":"113","author":"Das","year":"2009","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80874","article-title":"A Colitogenic Memory CD4+ T Cell Population Mediates Gastrointestinal Graft-Versus-Host Disease","volume":"126","author":"Zhou","year":"2016","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16624","article-title":"Interleukin-23 Receptor Signaling by Interleukin-39 Potentiates T Cell Pathogenicity in Acute Graft-Versus-Host Disease","volume":"21","author":"Bastian","year":"2021","journal-title":"Am J Transplant"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171199","article-title":"IL-12\/IL-23p40 Neutralization Blocks Th1\/Th17 Response After Allogeneic Hematopoietic Cell Transplantation","volume":"103","author":"Pidala","year":"2018","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine Signaling Modules in Inflammatory Responses","volume":"28","author":"O'Shea","year":"2008","journal-title":"Immunity"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.02.014","article-title":"Reduction of Graft-Versus-Host Disease by Histone Deacetylase Inhibitor Suberonylanilide Hydroxamic Acid is Associated With Modulation of Inflammatory Cytokine Milieu and Involves Inhibition of STAT1","volume":"34","author":"Leng","year":"2006","journal-title":"Exp Hematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43706","article-title":"Absence of Stat1 in Donor CD4\u207a T Cells Promotes the Expansion of Tregs and Reduces Graft-Versus-Host Disease in Mice","volume":"121","author":"Ma","year":"2011","journal-title":"J Clin Invest"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63776-5","article-title":"Kinetics of Gene Expression in Murine Cutaneous Graft-Versus-Host Disease","volume":"164","author":"Sugerman","year":"2004","journal-title":"Am J Pathol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e109799","DOI":"10.1371\/journal.pone.0109799","article-title":"Pharmacologic Blockade of JAK1\/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect","volume":"9","author":"Choi","year":"2014","journal-title":"PloS One"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2758","article-title":"Pharmacologic Inhibition of JAK1\/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects","volume":"21","author":"Carniti","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0123-z","article-title":"Baricitinib-Induced Blockade of Interferon Gamma Receptor and Interleukin-6 Receptor for the Prevention and Treatment of Graft-Versus-Host Disease","volume":"32","author":"Choi","year":"2018","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2015.09.002","article-title":"JAK1-STAT3 Blockade by JAK Inhibitor SHR0302 Attenuates Inflammatory Responses of Adjuvant-Induced Arthritis Rats and Decreases Th17 and Total B Cells","volume":"83","author":"Wu","year":"2016","journal-title":"Joint Bone Spine"},{"key":"B63","doi-asserted-by":"publisher","first-page":"9636897211033778","DOI":"10.1177\/09636897211033778","article-title":"Preventive and Therapeutic Effects of a Novel JAK Inhibitor SHR0302 in Acute Graft-Versus-Host Disease","volume":"30","author":"Sun","year":"2021","journal-title":"Cell Transplant"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in Corticosteroid-Refractory Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation: A Multicenter Survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of Therapeutic JAK 1\/2 Blockade in Graft-Versus-Host Disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-Versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001043","article-title":"A Phase 1 Trial of Itacitinib, a Selective JAK1 Inhibitor, in Patients With Acute Graft-Versus-Host Disease","volume":"4","author":"Schroeder","year":"2020","journal-title":"Blood Adv"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc0227","article-title":"Spatiotemporal Single-Cell Profiling Reveals That Invasive and Tissue-Resident Memory Donor CD8","volume":"13","author":"Tkachev","year":"2021","journal-title":"Sci Transl Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.05.011","article-title":"The Chemokine Receptor CCR5 Plays a Key Role in the Early Memory CD8+ T Cell Response to Respiratory Virus Infections","volume":"29","author":"Kohlmeier","year":"2008","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.5.2225","article-title":"Functional Expression of the Chemokine Receptor CCR5 on Virus Epitope-Specific Memory and Effector CD8+ T Cells","volume":"168","author":"Fukada","year":"2002","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.3.1746","article-title":"Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer","volume":"182","author":"Tan","year":"2009","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.060690","article-title":"CCR5 Deficiency Drives Enhanced Natural Killer Cell Trafficking to and Activation Within the Liver in Murine T Cell-Mediated Hepatitis","volume":"170","author":"Ajuebor","year":"2007","journal-title":"Am J Pathol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/ni879","article-title":"Peyer's Patch is the Essential Site in Initiating Murine Acute and Lethal Graft-Versus-Host Reaction","volume":"4","author":"Murai","year":"2003","journal-title":"Nat Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2003.12.003","article-title":"An Absence of CCR5 on Donor Cells Results in Acceleration of Acute Graft-vs-Host Disease","volume":"32","author":"Welniak","year":"2004","journal-title":"Exp Hematol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1632","article-title":"Critical Role for CCR5 in the Function of Donor CD4+CD25+ Regulatory T Cells During Acute Graft-Versus-Host Disease","volume":"106","author":"Wysocki","year":"2005","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201248","article-title":"Blockade of Lymphocyte Chemotaxis in Visceral Graft-Versus-Host Disease","volume":"367","author":"Reshef","year":"2012","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-735076","article-title":"Clinical and Immunologic Impact of CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis","volume":"129","author":"Moy","year":"2017","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.034","article-title":"Extended CCR5 Blockade for Graft-Versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial","volume":"25","author":"Reshef","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three Prophylaxis Regimens (Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide; Tacrolimus, Methotrexate, and Bortezomib; or Tacrolimus, Methotrexate, and Maraviroc) Versus Tacrolimus and Methotrexate for Prevention of Graft-Versus-Host Disease With Haemopoietic Cell Transplantation With Reduced-Intensity Conditioning: A Randomised Phase 2 Trial With a Non-Randomised Contemporaneous Control Group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"B80","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.159.4.1746","article-title":"Homing of Naive and Memory T Lymphocyte Subsets to Peyer's Patches, Lymph Nodes, and Spleen","volume":"159","author":"Williams","year":"1997","journal-title":"J Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0957","article-title":"LPAM (Alpha 4 Beta 7 Integrin) is an Important Homing Integrin on Alloreactive T Cells in the Development of Intestinal Graft-Versus-Host Disease","volume":"103","author":"Petrovic","year":"2004","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3445","article-title":"Absence of Beta7 Integrin Results in Less Graft-Versus-Host Disease Because of Decreased Homing of Alloreactive T Cells to Intestine","volume":"107","author":"Waldman","year":"2006","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2339","article-title":"L-Selectin and Beta7 Integrin on Donor CD4 T Cells are Required for the Early Migration to Host Mesenteric Lymph Nodes and Acute Colitis of Graft-Versus-Host Disease","volume":"106","author":"Dutt","year":"2005","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0306231","article-title":"Intervention of MAdCAM-1 or Fractalkine Alleviates Graft-Versus-Host Reaction Associated Intestinal Injury While Preserving Graft-Versus-Tumor Effects","volume":"81","author":"Ueha","year":"2007","journal-title":"J Leukoc Biol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.immuni.2019.06.003","article-title":"T Cell Recruitment to the Intestinal Stem Cell Compartment Drives Immune-Mediated Intestinal Damage After Allogeneic Transplantation","volume":"51","author":"Fu","year":"2019","journal-title":"Immunity"},{"key":"B86","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/bmt.2012.191","article-title":"Expression of \u03b14\u03b27 Integrin on Memory CD8(+) T Cells at the Presentation of Acute Intestinal GVHD","volume":"48","author":"Chen","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.11.013","article-title":"Safety and Effectiveness of Vedolizumab in Patients With Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: A Retrospective Record Review","volume":"25","author":"Fl\u00f8isand","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0094-8","article-title":"Vedolizumab for Treatment of Steroid-Refractory Lower Gastrointestinal Acute Graft-Versus-Host Disease","volume":"53","author":"Coltoff","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0364-5","article-title":"Anti-\u03b14\u03b27 Integrin Monoclonal Antibody (Vedolizumab) for the Treatment of Steroid-Resistant Severe Intestinal Acute Graft-Versus-Host Disease","volume":"54","author":"Danylesko","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B90","doi-asserted-by":"publisher","first-page":"272.e271","DOI":"10.1016\/j.jtct.2020.12.011","article-title":"Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease","volume":"27","author":"Mehta","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01356-0","article-title":"A Phase 2a Randomized Clinical Trial of Intravenous Vedolizumab for the Treatment of Steroid-Refractory Intestinal Acute Graft-Versus-Host Disease","volume":"56","author":"Fl\u00f8isand","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.01.016","article-title":"Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3","volume":"22","author":"Fontenot","year":"2005","journal-title":"Immunity"},{"key":"B93","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","article-title":"Foxp3+ CD25+ CD4+ Natural Regulatory T Cells in Dominant Self-Tolerance and Autoimmune Disease","volume":"212","author":"Sakaguchi","year":"2006","journal-title":"Immunol Rev"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030152","article-title":"Conversion of Peripheral CD4+CD25- Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-Beta Induction of Transcription Factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J Exp Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5149","article-title":"Cutting Edge: TGF-Beta Induces a Regulatory Phenotype in CD4+CD25- T Cells Through Foxp3 Induction and Down-Regulation of Smad7","volume":"172","author":"Fantini","year":"2004","journal-title":"J Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00163","article-title":"The Role of Regulatory T Cells in the Biology of Graft Versus Host Disease","volume":"4","author":"Beres","year":"2013","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3493","article-title":"The Infusion of Ex Vivo Activated and Expanded CD4(+)CD25(+) Immune Regulatory Cells Inhibits Graft-Versus-Host Disease Lethality","volume":"99","author":"Taylor","year":"2002","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1850","article-title":"L-Selectin(hi) But Not the L-Selectin(Lo) CD4+25+ T-Regulatory Cells are Potent Inhibitors of GVHD and BM Graft Rejection","volume":"104","author":"Taylor","year":"2004","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ Regulatory T Cells Preserve Graft-Versus-Tumor Activity While Inhibiting Graft-Versus-Host Disease After Bone Marrow Transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1011510","article-title":"Donor- But Not Host-Derived Interleukin-10 Contributes to the Regulation of Experimental Graft-Versus-Host Disease","volume":"91","author":"Tawara","year":"2012","journal-title":"J Leukoc Biol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001625","article-title":"A Crucial Role for Host APCs in the Induction of Donor CD4+CD25+ Regulatory T Cell-Mediated Suppression of Experimental Graft-Versus-Host Disease","volume":"185","author":"Tawara","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of Ex Vivo Expanded T Regulatory Cells in Adults Transplanted With Umbilical Cord Blood: Safety Profile and Detection Kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.05.005","article-title":"Immunoselection and Clinical Use of T Regulatory Cells in HLA-Haploidentical Stem Cell Transplantation","volume":"24","author":"Di Ianni","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127244","article-title":"Transplantation of Donor Grafts With Defined Ratio of Conventional and Regulatory T Cells in HLA-Matched Recipients","volume":"4","author":"Meyer","year":"2019","journal-title":"JCI Insight"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003219","article-title":"First-In-Human Phase 1 Trial of Induced Regulatory T Cells for Graft-Versus-Host Disease Prophylaxis in HLA-Matched Siblings","volume":"5","author":"MacMillan","year":"2021","journal-title":"Blood Adv"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-365247","article-title":"Inhibition of IL-32 Activation by \u03b1-1 Antitrypsin Suppresses Alloreactivity and Increases Survival in an Allogeneic Murine Marrow Transplantation Model","volume":"118","author":"Marcondes","year":"2011","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003336","article-title":"Biomarker-Guided Preemption of Steroid-Refractory Graft-Versus-Host Disease With \u03b1-1-Antitrypsin","volume":"4","author":"Gergoudis","year":"2020","journal-title":"Blood Adv"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.05.011","article-title":"Response of Steroid-Refractory Acute GVHD to \u03b11-Antitrypsin","volume":"22","author":"Marcondes","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone Deacetylase Inhibitors: Molecular Mechanisms of Action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nrd772","article-title":"Histone-Deacetylase Inhibitors: Novel Drugs for the Treatment of Cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.2.169","article-title":"Histone Deacetylase Inhibitors: Possible Implications for Neurodegenerative Disorders","volume":"17","author":"Hahnen","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"B112","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1755-5949.2010.00203.x","article-title":"Histone Deacetylases and Mood Disorders: Epigenetic Programming in Gene-Environment Interactions","volume":"17","author":"Machado-Vieira","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21403","article-title":"Importance of Disrupted Intestinal Barrier in Inflammatory Bowel Diseases","volume":"17","author":"Salim","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200625101442","article-title":"Cinnamyl Sulfonamide Hydroxamate Derivatives Inhibited LPS-Stimulated NF-kB Expression in RAW 264.7 Cells","volume":"26","author":"Joshi","year":"2020","journal-title":"Curr Pharm Des"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-019-0135-7","article-title":"HDAC Inhibitors Promote Intestinal Epithelial Regeneration via Autocrine Tgf\u03b21 Signalling in Inflammation","volume":"12","author":"Friedrich","year":"2019","journal-title":"Mucosal Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00007","article-title":"HDAC Inhibition and Graft Versus Host Disease","volume":"17","author":"Choi","year":"2011","journal-title":"Mol Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.3390\/ijms21124281","article-title":"Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia","volume":"21","author":"Kim","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641910","article-title":"Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-Vs.-Host Disease After Allogeneic Stem Cell Transplantation","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0400380101","article-title":"Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Reduces Acute Graft-Versus-Host Disease and Preserves Graft-Versus-Leukemia Effect","volume":"101","author":"Reddy","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1172\/JCI34712","article-title":"Histone Deacetylase Inhibition Modulates Indoleamine 2,3-Dioxygenase-Dependent DC Functions and Regulates Experimental Graft-Versus-Host Disease in Mice","volume":"118","author":"Reddy","year":"2008","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(13)70512-6","article-title":"Vorinostat Plus Tacrolimus and Mycophenolate to Prevent Graft-Versus-Host Disease After Related-Donor Reduced-Intensity Conditioning Allogeneic Haemopoietic Stem-Cell Transplantation: A Phase 1\/2 Trial","volume":"15","author":"Choi","year":"2014","journal-title":"Lancet Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-790469","article-title":"Vorinostat Plus Tacrolimus\/Methotrexate to Prevent GVHD After Myeloablative Conditioning, Unrelated Donor HCT","volume":"130","author":"Choi","year":"2017","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0163-z","article-title":"Phase I Trial of Histone Deacetylase Inhibitor Panobinostat in Addition to Glucocorticoids for Primary Therapy of Acute Graft-Versus-Host Disease","volume":"53","author":"Perez","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004225","article-title":"A Phase 2 Trial of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease Prevention","volume":"5","author":"Perez","year":"2021","journal-title":"Blood Adv"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome Inhibitor Drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B126","article-title":"The Ubiquitin-Proteasome System and its Role in Inflammatory and Autoimmune Diseases","volume":"3","author":"Wang","year":"2006","journal-title":"Cell Mol Immunol"},{"key":"B127","article-title":"Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0212736","article-title":"Proteasome Inhibition Reduces Superantigen-Mediated T Cell Activation and the Severity of Psoriasis in a SCID-Hu Model","volume":"109","author":"Zollner","year":"2002","journal-title":"J Clin Invest"},{"key":"B129","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0091-6749(99)70369-6","article-title":"Proteasome Inhibition: A Novel Mechanism to Combat Asthma","volume":"104","author":"Elliott","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120030218","article-title":"Development of the Proteasome Inhibitor Velcade (Bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Invest"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1177\/107327480301000502","article-title":"Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers","volume":"10","author":"Richardson","year":"2003","journal-title":"Cancer Control"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0401563101","article-title":"Inhibition of Acute Graft-Versus-Host Disease With Retention of Graft-Versus-Tumor Effects by the Proteasome Inhibitor Bortezomib","volume":"101","author":"Sun","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1820","article-title":"NF-kappaB as a Target for the Prevention of Graft-Versus-Host Disease: Comparative Efficacy of Bortezomib and PS-1145","volume":"107","author":"Vodanovic-Jankovic","year":"2006","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143461","article-title":"Differential Effects of Donor T-Cell Cytokines on Outcome With Continuous Bortezomib Administration After Allogeneic Bone Marrow Transplantation","volume":"112","author":"Sun","year":"2008","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.03.042","article-title":"The Protection and Therapy Effects of Bortezomib in Murine Acute Graft-Versus-Host Disease","volume":"45","author":"Li","year":"2013","journal-title":"Transplant Proc"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation","volume":"30","author":"Koreth","year":"2012","journal-title":"J Clin Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.027","article-title":"A Bortezomib-Based Regimen Offers Promising Survival and Graft-Versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial","volume":"21","author":"Koreth","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.176859","article-title":"Bortezomib-Based Immunosuppression After Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation: Randomized Phase II Results","volume":"103","author":"Koreth","year":"2018","journal-title":"Haematologica"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.779076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T15:50:14Z","timestamp":1673884214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.779076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":138,"alternative-id":["10.3389\/fimmu.2021.779076"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.779076","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,26]]},"article-number":"779076"}}